A citation-based method for searching scientific literature

Andrew Nguyen, Louisa Ho, Samuel T Workenhe, Lan Chen, Jonathan Samson, Scott R Walsh, Jonathan Pol, Jonathan L Bramson, Yonghong Wan. Cell Rep 2018
Times Cited: 12







List of co-cited articles
53 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Ashley Orillion, Ayumi Hashimoto, Nur Damayanti, Li Shen, Remi Adelaiye-Ogala, Sreevani Arisa, Sreenivasulu Chintala, Peter Ordentlich, Chingai Kao, Bennett Elzey,[...]. Clin Cancer Res 2017
202
33

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Li Shen, Michael Ciesielski, Swathi Ramakrishnan, Kiersten M Miles, Leigh Ellis, Paula Sotomayor, Protul Shrikant, Robert Fenstermaker, Roberto Pili. PLoS One 2012
128
25

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Sofia R Gameiro, Anthony S Malamas, Kwong Y Tsang, Soldano Ferrone, James W Hodge. Oncotarget 2016
56
25

HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Siyu Deng, Qianwen Hu, Heng Zhang, Fang Yang, Cheng Peng, Chuanxin Huang. Mol Cancer Ther 2019
46
25

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
Karin M Knudson, Kristin C Hicks, Xiaoling Luo, Jin-Qiu Chen, Jeffrey Schlom, Sofia R Gameiro. Oncoimmunology 2018
113
16

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Kristin C Hicks, Massimo Fantini, Renee N Donahue, Angie Schwab, Karin M Knudson, Sarah R Tritsch, Caroline Jochems, Paul E Clavijo, Clint T Allen, James W Hodge,[...]. Oncoimmunology 2018
38
16

HDAC inhibitors and immunotherapy; a double edged sword?
Michiel Kroesen, Paul Gielen, Ingrid C Brok, Inna Armandari, Peter M Hoogerbrugge, Gosse J Adema. Oncotarget 2014
115
16


Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Jeenah Park, Scott Thomas, Pamela N Munster. Epigenomics 2015
34
16

Entinostat: a promising treatment option for patients with advanced breast cancer.
Roisin M Connolly, Michelle A Rudek, Richard Piekarz. Future Oncol 2017
57
16

Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line.
P F Robbins, J A Kantor, M Salgaller, P H Hand, P D Fernsten, J Schlom. Cancer Res 1991
149
16

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
KiBem Kim, Andrew D Skora, Zhaobo Li, Qiang Liu, Ada J Tam, Richard L Blosser, Luis A Diaz, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein,[...]. Proc Natl Acad Sci U S A 2014
417
16

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Qin C Ryan, Donna Headlee, Milin Acharya, Alex Sparreboom, Jane B Trepel, Joseph Ye, William D Figg, Kyunghwa Hwang, Eun Joo Chung, Anthony Murgo,[...]. J Clin Oncol 2005
333
16


Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells.
Mareike Schmudde, André Braun, Daniela Pende, Jürgen Sonnemann, Ulrike Klier, James F Beck, Lorenzo Moretta, Barbara M Bröker. Cancer Lett 2008
52
16

Trafficking of T cells into tumors.
Clare Y Slaney, Michael H Kershaw, Phillip K Darcy. Cancer Res 2014
225
16


Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.
M E Mikucki, D T Fisher, J Matsuzaki, J J Skitzki, N B Gaulin, J B Muhitch, A W Ku, J G Frelinger, K Odunsi, T F Gajewski,[...]. Nat Commun 2015
275
16

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas.
Ophélia Maertens, Ryan Kuzmickas, Haley E Manchester, Chloe E Emerson, Alessandra G Gavin, Caroline J Guild, Terence C Wong, Thomas De Raedt, Christian Bowman-Colin, Elodie Hatchi,[...]. Cancer Discov 2019
39
16

HDAC3 functions as a positive regulator in Notch signal transduction.
Francesca Ferrante, Benedetto Daniele Giaimo, Marek Bartkuhn, Tobias Zimmermann, Viola Close, Daniel Mertens, Andrea Nist, Thorsten Stiewe, Johanna Meier-Soelch, Michael Kracht,[...]. Nucleic Acids Res 2020
15
16

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Meredith L Stone, Katherine B Chiappinelli, Huili Li, Lauren M Murphy, Meghan E Travers, Michael J Topper, Dimitrios Mathios, Michael Lim, Ie-Ming Shih, Tian-Li Wang,[...]. Proc Natl Acad Sci U S A 2017
138
16


Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function.
Eva Sahakian, John J Powers, Jie Chen, Susan L Deng, Fengdong Cheng, Allison Distler, David M Woods, Jennifer Rock-Klotz, Andressa L Sodre, Je-In Youn,[...]. Mol Immunol 2015
76
16

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Michael F Emmons, Fernanda Faião-Flores, Ritin Sharma, Ram Thapa, Jane L Messina, Jurgen C Becker, Dirk Schadendorf, Edward Seto, Vernon K Sondak, John M Koomen,[...]. Cancer Res 2019
36
16

HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.
Yue Xue, Wenwen Lian, Jiaqi Zhi, Wenjuan Yang, Qianjin Li, Xingyi Guo, Jiahao Gao, Hao Qu, Weiqiang Lin, Zhongqi Li,[...]. Br J Cancer 2019
17
16

Potentiating cancer immunotherapy using an oncolytic virus.
Byram W Bridle, Kyle B Stephenson, Jeanette E Boudreau, Sandeep Koshy, Natasha Kazdhan, Eleanor Pullenayegum, Jérôme Brunellière, Jonathan L Bramson, Brian D Lichty, Yonghong Wan. Mol Ther 2010
115
16

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.
D F Stojdl, B Lichty, S Knowles, R Marius, H Atkins, N Sonenberg, J C Bell. Nat Med 2000
627
16

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.
Jun Li, Mark O'Malley, Julie Urban, Padma Sampath, Z Sheng Guo, Pawel Kalinski, Steve H Thorne, David L Bartlett. Mol Ther 2011
97
16

Maraba virus as a potent oncolytic vaccine vector.
Jonathan G Pol, Liang Zhang, Byram W Bridle, Kyle B Stephenson, Julien Rességuier, Stephen Hanson, Lan Chen, Natasha Kazdhan, Jonathan L Bramson, David F Stojdl,[...]. Mol Ther 2014
102
16

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9.
Elizabeth C Eckert, Rebecca A Nace, Jason M Tonne, Laura Evgin, Richard G Vile, Stephen J Russell. Mol Ther Oncolytics 2019
14
16

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.
Edmund K Moon, Liang-Chuan S Wang, Kheng Bekdache, Rachel C Lynn, Albert Lo, Stephen H Thorne, Steven M Albelda. Oncoimmunology 2018
76
16

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Caroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H Thorne, Richard Patt, Manijeh Daneshmand, Anne Moon, Carolina Ilkow, James Burke, Tae-Ho Hwang,[...]. Cancer Res 2013
145
16

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.
Meijun Zheng, Jianhan Huang, Aiping Tong, Hui Yang. Mol Ther Oncolytics 2019
90
16

Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.
Zong Sheng Guo, Zuqiang Liu, David L Bartlett. Front Oncol 2014
169
16

Cancer immunotherapy using checkpoint blockade.
Antoni Ribas, Jedd D Wolchok. Science 2018
16

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Christopher S Garris, Sean P Arlauckas, Rainer H Kohler, Marcel P Trefny, Seth Garren, Cécile Piot, Camilla Engblom, Christina Pfirschke, Marie Siwicki, Jeremy Gungabeesoon,[...]. Immunity 2018
399
16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
16

The emerging role of epigenetic therapeutics in immuno-oncology.
Michael J Topper, Michelle Vaz, Kristen A Marrone, Julie R Brahmer, Stephen B Baylin. Nat Rev Clin Oncol 2020
131
16

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Young-Dae Kim, Sang-Min Park, Hae Chan Ha, A Reum Lee, Heeyoung Won, Hyunju Cha, Sangsook Cho, Joong Myung Cho. J Cancer 2020
42
16

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Johannes Laengle, Julijan Kabiljo, Leah Hunter, Jakob Homola, Sophie Prodinger, Gerda Egger, Michael Bergmann. J Immunother Cancer 2020
16
16

PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Haidong Tang, Yong Liang, Robert A Anders, Janis M Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan M Harrington, Jingya Guo, Yangchun Xin,[...]. J Clin Invest 2018
278
16

Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
Daphné Morel, Daniel Jeffery, Sandrine Aspeslagh, Geneviève Almouzni, Sophie Postel-Vinay. Nat Rev Clin Oncol 2020
145
16

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Jennifer L Guerriero, Alaba Sotayo, Holly E Ponichtera, Jessica A Castrillon, Alexandra L Pourzia, Sara Schad, Shawn F Johnson, Ruben D Carrasco, Suzan Lazo, Roderick T Bronson,[...]. Nature 2017
297
16

Epigenetic control of CD8+ T cell differentiation.
Amanda N Henning, Rahul Roychoudhuri, Nicholas P Restifo. Nat Rev Immunol 2018
187
16

Epigenetic therapy inhibits metastases by disrupting premetastatic niches.
Zhihao Lu, Jianling Zou, Shuang Li, Michael J Topper, Yong Tao, Hao Zhang, Xi Jiao, Wenbing Xie, Xiangqian Kong, Michelle Vaz,[...]. Nature 2020
111
16

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
16

Coinhibitory Pathways in Immunotherapy for Cancer.
Susanne H Baumeister, Gordon J Freeman, Glenn Dranoff, Arlene H Sharpe. Annu Rev Immunol 2016
498
16

Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Kristin C Hicks, Karin M Knudson, Karin L Lee, Duane H Hamilton, James W Hodge, William D Figg, Peter Ordentlich, Frank R Jones, Shahrooz Rabizadeh, Patrick Soon-Shiong,[...]. Clin Cancer Res 2020
14
16

Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.
Rong En Tay, Olamide Olawoyin, Paloma Cejas, Yingtian Xie, Clifford A Meyer, Yoshinaga Ito, Qing Yu Weng, David E Fisher, Henry W Long, Myles Brown,[...]. J Exp Med 2020
18
16

HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.
Ji Cao, Lei Sun, Pornpun Aramsangtienchai, Nicole A Spiegelman, Xiaoyu Zhang, Weishan Huang, Edward Seto, Hening Lin. Proc Natl Acad Sci U S A 2019
75
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.